BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11553045)

  • 1. Determination of a positive malignant hyperthermia (MH) disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation.
    Rueffert H; Olthoff D; Deutrich C; Froster UG
    Clin Genet; 2001 Aug; 60(2):117-24. PubMed ID: 11553045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
    Rueffert H; Olthoff D; Deutrich C; Meinecke CD; Froster UG
    Acta Anaesthesiol Scand; 2002 Jul; 46(6):692-8. PubMed ID: 12059893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro contracture test and gene typing in diagnosing malignant hyperthermia. Each as an appropriate complement to the other method].
    Rüffert H; Olthoff D; Deutrich C; Thamm B; Froster U
    Anaesthesist; 2000 Feb; 49(2):113-20. PubMed ID: 10756965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous and heterozygous Arg614Cys mutations (1840C-->T) in the ryanodine receptor gene co-segregate with malignant hyperthermia susceptibility in a German family.
    Rueffert H; Olthoff D; Deutrich C; Thamm B; Froster UG
    Br J Anaesth; 2001 Aug; 87(2):240-5. PubMed ID: 11493496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response.
    Steinfath M; Singh S; Scholz J; Becker K; Lenzen C; Wappler F; Köchling A; Roewer N; Schulte am Esch J
    J Mol Med (Berl); 1995 Jan; 73(1):35-40. PubMed ID: 7633940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
    Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
    Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
    Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
    Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
    Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of discordance between genotype and phenotype in a malignant hyperthermia family.
    Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F
    Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for mutations in the RYR1 gene in families with malignant hyperthermia.
    Muniz VP; Silva HC; Tsanaclis AM; Vainzof M
    J Mol Neurosci; 2003; 21(1):35-42. PubMed ID: 14500992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new mutation in the skeletal ryanodine receptor gene (RYR1) is potentially causative of malignant hyperthermia, central core disease, and severe skeletal malformation.
    Rueffert H; Olthoff D; Deutrich C; Schober R; Froster UG
    Am J Med Genet A; 2004 Jan; 124A(3):248-54. PubMed ID: 14708096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
    Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant hyperthermia susceptibility, an autosomal dominant disorder?
    Fagerlund TH; Islander G; Ranklev Twetman E; Berg K
    Clin Genet; 1997 Jun; 51(6):365-9. PubMed ID: 9237497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotype-phenotype comparison of the Swiss malignant hyperthermia population.
    Girard T; Urwyler A; Censier K; Mueller CR; Zorzato F; Treves S
    Hum Mutat; 2001 Oct; 18(4):357-8. PubMed ID: 11668625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current aspects of the diagnosis of malignant hyperthermia].
    Rüffert H; Olthoff D; Deutrich C; Froster UG
    Anaesthesist; 2002 Nov; 51(11):904-13. PubMed ID: 12434264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
    Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K
    Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
    Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetic detection of susceptibility to malignant hyperthermia in Belgian families.
    Heytens L
    Acta Anaesthesiol Belg; 2007; 58(2):113-8. PubMed ID: 17710899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
    Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
    Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
    Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.